Delphinus Medical Technologies, a Michigan developer of SoftVue, a whole breast ultrasound system that incorporates a ring transducer design, has named Mark J. Forchette president and CEO.
Previously, Forchette was president and CEO of OptiMedica, an ophthalmic medical device company. He led the start-up venture through development and growth, successfully completed multiple rounds of financing and oversaw the company’s acquisition by Abbott Laboratories in 2013. He began his career in the medtech industry as a sales representative at Greishaber, where he became vice president of U.S. sales and marketing and led the company through its acquisition by Alcon.
Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a circular transducer technology to transmit and receive ultrasound signals. SoftVue captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast, something no other currently available ultrasound system can do. With a short scan time of one to two minutes per breast, SoftVue presents a complete image map of the whole breast, providing a consistent and uniform exam without reliance on operator skill and technique.
In recent years, it has become understood that dense breast tissue can obscure breast cancer, rendering mammography ineffective for 40% of women in the U.S. With growing state legislation requiring women to be notified of their breast tissue density, new non-radiation imaging solutions are needed for the health professionals engaged every day in bettering breast health.